Empagliflozin and dapagliflozin, two members of sodium-glucose cotransporter 2 inhibitors (SGLT2i) which promote urinary glucose loss, profoundly reduce the risk of hospitalization for heart failure (HF) across broad range of patient characteristics1–3. Here, SLC5A2 is linked to hydrops fetalis.